NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky announces it has commenced an investigation of Endologix Inc. (NASDAQ:ELGX) (“Endologix”) concerning possible violations of federal securities laws by the Company and/or certain of its officers and directors.
On August 2, 2016, CEO John McDermott stated that Endologix would seek approval of the original version of the Nellix system that was used in the Nellix investigational device exemption (“IDE”) clinical trial, the EVAS FORWARD-IDE Study, given that Endologix had the needed clinical data. Then on November 16, 2016, Endologix announced that the U.S. Food & Drug Administration requested two-year follow-up data on patients enrolled in the EVAS-FORWARD-IDE study to assess Nellix. When this news was announced, shares of Endologix fell in value. To obtain additional information, go to:
or contact Joseph E. Levi, Esq. either via email at email@example.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.
Levi & Korsinsky, LLP
Eduard Korsinsky, Esq.
30 Broad Street - 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171